PPF方案辅加复方丹参滴丸对中晚期食管癌的疗效观察

Evaluate the Effect of Composite Salviae Dropping Pill Combined with PPF Regimen Chemotherapy in Patients with Advanced Esophageal Carcinoma

目的 探讨复方丹参滴丸对提高中晚期食管癌化疗疗效和不良反应的影响。方法 70例中晚期食管癌患者随机分为A、B 2组,A组(3 6例)采用复方丹参滴丸加PPF方案治疗,B组(3 4例)采用单纯PPF方案化疗。对疗效、生活质量及不良反应进行评定。结果 A、B 2组的有效率(CR +PR )分别为5 2 .8% (19/3 6)和3 8.2 % (13 /3 4) (P >0 .0 5 ) ;A、B 2组临床获益率(CR +PR +SD )分别为80 .6% (2 9/3 6)和5 2 .9% (18/3 4) (P <0 .0 5 )。A组中位生存期为3 6周、B组为3 0周。A组治疗后T淋巴细胞亚群中的CD4/CD8比值显著提高(P <0 .0 5 ) ,B组治疗前后无明显变化(P >0 .0 5 )。A组生活质量高于B组(P <0 .0 5 )。B组Ⅱ～Ⅳ度白细胞减少、恶心呕吐反应及黏膜炎发生率高于A组(P <0 .0 5 )。结论 复方丹参滴丸可增强化疗药物的抗肿瘤作用,有助于提高患者治疗的临床获益率、延长中位生存时间、减轻化疗某些不良反应、改善生活质量。

Objective To observe whether Composite Salviae Dropping Pill improve chemotherapy efficacy and abates chemotherapy reaction of Advanced Esophageal Carcinoma.Methods 70 patients with advanced esophageal carcinoma were randomly divided to receive PPF regimen combined with Composite Salviae Dropping Pill(group A,36 cases) or only PPF regimen(group B,34 cases).The effect of treatment,quality of life,toxicity were observe.Results The objective response rate(CR+PR) was 52.8%(19/36) in group A,compared to 38.2%(13/34) in group B(P>0.05),the clinical benefit response rate(CR+PR+SD) was 80.6%(29/36) in group A,compared to 52.9%(18/34) in group B(P<0.05).The median survival was 36 weeks in group A,which was higher than that in group B(30 weeks).the level of CD4/CD8 was significantly increased in group A,whereas no change was found in group B,quality of life in group A was higher than that in group B(P<0.05),Ⅱ～Ⅳ Leukopenia?nausea?vomiting?mucitis in group B were more serious than those in group(P<0.05).Conclusion Composite Salviae Dropping Pill has some functions of potentiation the antitumor effects of chemotherapy,giving a satisfactory stable rate though not very high,decreasing side effects of chemotherapy,elongating median survival time,improving quality of the patients with advanced esophageal carcinoma of the patients with advanced esophageal carcinoma treated with chemotherapy.